Container closures are critical to ensure sterility of drug products. Physical, chemical, and biological assessments must be made to ensure components are compatible and fit for use. Additionally, USP 661.1, 661.2, & 382 will be official by end of year 2025. This webinar will review the changes these new general chapters bring.
By attending the webinar you will learn:
• Container closure requirements for parenteral products
• What changes are brought with USP 661.1, 661.2, & 382
• Nelson Lab’s capabilities to meet new chapter requirements.
Presented by Logan Luke and Shiri Hechter